Merck KGaA: Stifel reduces target price

(CercleFinance.com) - Stifel confirms its Buy rating on Merck KGaA shares, with a target price reduced from E194 to E185.


The analyst believes that Q3 is unlikely to be controversial, as all three divisions face some uncertainty for FY 2025: Healthcare on licensing agreements and pipeline, Life Sciences on 2025 forecasts and potential M&A deals, and Electronics on the recovery of previous-generation products.

We have made minor adjustments to our estimates for fiscal 2024, due to heightened caution regarding the Healthcare division and the recovery trajectory in Life Sciences, the broker says.

Finally, Stifel reports that Merck is 'attractively valued' relative to its end markets and competitors.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.